Diabetes · Chicago area, IL
Diabetes studies in Chicago area, IL
34 recruiting studies have a site in the Chicago area. This page includes nearby cities such as Evanston, Oak Brook, Oak Lawn, Park Ridge.
34 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of…
AstraZeneca
- Location
- Chicago, IL + 3 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteers
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Cleerly, Inc.
- Location
- Chicago, IL + 121 other US sites
- Eligibility basics
- Ages 55+
- RecruitingHealthy volunteers
Food and Metabolism Study
Clinical Nutrition Research Center, Illinois Institute of Technology
- Location
- Chicago, IL
- Eligibility basics
- Ages 40–70
- RecruitingPhase 2
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
Hanmi Pharmaceutical Company Limited
- Location
- Chicago, IL + 19 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
Sonavex, Inc.
- Location
- Chicago, IL + 19 other US sites
- Eligibility basics
- Ages 18–84
- RecruitingPhase 2/Phase 3
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
AbbVie
- Location
- Chicago, IL + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Chicago, IL + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Boehringer Ingelheim
- Location
- Chicago, IL + 199 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- Gurnee, IL + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Pfizer
- Location
- Chicago, IL + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Regeneron Pharmaceuticals
- Location
- Chicago, IL + 20 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Regeneron Pharmaceuticals
- Location
- Chicago, IL + 55 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Skokie, IL + 59 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Chicago, IL + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
Sparrow Pharmaceuticals
- Location
- Chicago, IL + 60 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Amgen
- Location
- Skokie, IL + 30 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Novo Nordisk A/S
- Location
- Skokie, IL + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Eli Lilly and Company
- Location
- Chicago, IL + 34 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
Corxel Pharmaceuticals
- Location
- Chicago, IL + 32 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1/Phase 2
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
COUR Pharmaceutical Development Company, Inc.
- Location
- Chicago, IL + 44 other US sites
- Eligibility basics
- Ages 12–35
- RecruitingPhase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Novo Nordisk A/S
- Location
- Chicago, IL + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
Vertex Pharmaceuticals Incorporated
- Location
- Chicago, IL + 9 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and…
Novo Nordisk A/S
- Location
- Gurnee, IL + 55 other US sites
- Eligibility basics
- Ages 45+
- Recruiting
MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors
Clinical Nutrition Research Center, Illinois Institute of Technology
- Location
- Chicago, IL
- Eligibility basics
- Ages 40–60
Who these studies look for
Studies commonly set an HbA1c range, a diagnosis duration and a list of allowed or excluded medications. Some also recruit people without diabetes as a comparison group.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.